Do analysts prefer ADIL or XCUR?

Adial Pharmaceuticals currently has a consensus price target of $17.17, suggesting a potential upside of 509.83%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Adial Pharmaceuticals is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ADIL or XCUR more profitable?

Adial Pharmaceuticals' return on equity of -162.82% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -162.82% -127.58% Exicure N/A -179.41% -64.37%

Does the media prefer ADIL or XCUR?

In the previous week, Adial Pharmaceuticals had 2 more articles in the media than Exicure. MarketBeat recorded 7 mentions for Adial Pharmaceuticals and 5 mentions for Exicure. Exicure's average media sentiment score of 0.57 beat Adial Pharmaceuticals' score of 0.45 indicating that Exicure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exicure 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, MDCX or ADIL?

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medicus Pharma N/A N/A -$35.46M -$2.68 N/A Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A

Is MDCX or ADIL more profitable?

Adial Pharmaceuticals' return on equity of -162.82% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -311.33% Adial Pharmaceuticals N/A -162.82% -127.58%

Does the media refer more to MDCX or ADIL?

In the previous week, Medicus Pharma had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 8 mentions for Medicus Pharma and 7 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 0.45 beat Medicus Pharma's score of 0.30 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Adial Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AEON or ADIL?

Adial Pharmaceuticals has a consensus price target of $17.17, suggesting a potential upside of 509.83%. Given Adial Pharmaceuticals' higher probable upside, analysts clearly believe Adial Pharmaceuticals is more favorable than AEON Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Adial Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has better earnings & valuation, AEON or ADIL?

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AEON Biopharma N/A N/A -$36.63M -$5.00 N/A Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A

Is AEON or ADIL more profitable?

AEON Biopharma's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets AEON Biopharma N/A N/A -994.63% Adial Pharmaceuticals N/A -162.82% -127.58%

Which has better valuation and earnings, ADIL or AKTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Is ADIL or AKTX more profitable?

Akari Therapeutics' return on equity of -123.29% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -162.82% -127.58% Akari Therapeutics N/A -123.29% -63.01%

Which has stronger earnings & valuation, PASG or ADIL?

Passage Bio is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Passage Bio N/A N/A -$45.52M -$11.84 N/A Adial Pharmaceuticals N/A N/A -$7.98M -$7.98 N/A

Is PASG or ADIL more profitable?

Passage Bio's return on equity of -150.88% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Passage Bio N/A -150.88% -59.78% Adial Pharmaceuticals N/A -162.82% -127.58%

Does the media prefer PASG or ADIL?

In the previous week, Adial Pharmaceuticals had 4 more articles in the media than Passage Bio. MarketBeat recorded 7 mentions for Adial Pharmaceuticals and 3 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.62 beat Adial Pharmaceuticals' score of 0.45 indicating that Passage Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adial Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Adial Pharmaceuticals (ADIL) Competitors

$2.82 -0.17 (-5.54%)

As of 12:01 PM Eastern

Compare

ADIL vs. XCUR, MDCX, AEON, AKTX, and PASG

Should you buy Adial Pharmaceuticals stock or one of its competitors? MarketBeat compares Adial Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adial Pharmaceuticals include Exicure (XCUR), Medicus Pharma (MDCX), AEON Biopharma (AEON), Akari Therapeutics (AKTX), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry.

How does Adial Pharmaceuticals compare to Exicure?

Adial Pharmaceuticals (NASDAQ:ADIL) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Adial Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Exicure has a beta of 3.53, indicating that its share price is 253% more volatile than the broader market.

Adial Pharmaceuticals currently has a consensus price target of $17.17, suggesting a potential upside of 509.83%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Adial Pharmaceuticals is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Adial Pharmaceuticals had 2 more articles in the media than Exicure. MarketBeat recorded 7 mentions for Adial Pharmaceuticals and 5 mentions for Exicure. Exicure's average media sentiment score of 0.57 beat Adial Pharmaceuticals' score of 0.45 indicating that Exicure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adial Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exicure has higher revenue and earnings than Adial Pharmaceuticals. Exicure is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A
Exicure	$500K	35.42	-$4.95M	-$1.55	N/A

16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 1.9% of Adial Pharmaceuticals shares are owned by insiders. Comparatively, 52.8% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Adial Pharmaceuticals' return on equity of -162.82% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-162.82%	-127.58%
Exicure	N/A	-179.41%	-64.37%

Summary

Exicure beats Adial Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Adial Pharmaceuticals' return on equity of -162.82% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-311.33%
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 8.1% of Medicus Pharma shares are owned by company insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Medicus Pharma had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 8 mentions for Medicus Pharma and 7 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 0.45 beat Medicus Pharma's score of 0.30 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Adial Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

Medicus Pharma currently has a consensus price target of $9.00, suggesting a potential upside of 2,635.56%. Adial Pharmaceuticals has a consensus price target of $17.17, suggesting a potential upside of 509.83%. Given Medicus Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Medicus Pharma is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Medicus Pharma has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Summary

Medicus Pharma and Adial Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to AEON Biopharma?

AEON Biopharma (NASDAQ:AEON) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

AEON Biopharma has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Adial Pharmaceuticals has a consensus price target of $17.17, suggesting a potential upside of 509.83%. Given Adial Pharmaceuticals' higher probable upside, analysts clearly believe Adial Pharmaceuticals is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by company insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

In the previous week, Adial Pharmaceuticals had 7 more articles in the media than AEON Biopharma. MarketBeat recorded 7 mentions for Adial Pharmaceuticals and 0 mentions for AEON Biopharma. Adial Pharmaceuticals' average media sentiment score of 0.45 beat AEON Biopharma's score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
AEON Biopharma	Neutral
Adial Pharmaceuticals	Neutral

AEON Biopharma's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

Summary

AEON Biopharma and Adial Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Akari Therapeutics?

Adial Pharmaceuticals (NASDAQ:ADIL) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Akari Therapeutics' return on equity of -123.29% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-162.82%	-127.58%
Akari Therapeutics	N/A	-123.29%	-63.01%

Adial Pharmaceuticals has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

Adial Pharmaceuticals currently has a consensus target price of $17.17, suggesting a potential upside of 509.83%. Akari Therapeutics has a consensus target price of $89.00, suggesting a potential upside of 561.96%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akari Therapeutics is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 1.9% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 32.2% of Akari Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Adial Pharmaceuticals had 6 more articles in the media than Akari Therapeutics. MarketBeat recorded 7 mentions for Adial Pharmaceuticals and 1 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 1.89 beat Adial Pharmaceuticals' score of 0.45 indicating that Akari Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Adial Pharmaceuticals	Neutral
Akari Therapeutics	Very Positive

Summary

Akari Therapeutics beats Adial Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Passage Bio?

Passage Bio (NASDAQ:PASG) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by company insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Passage Bio is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

Passage Bio presently has a consensus target price of $13.25, suggesting a potential upside of 133.11%. Adial Pharmaceuticals has a consensus target price of $17.17, suggesting a potential upside of 509.83%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Adial Pharmaceuticals is more favorable than Passage Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Passage Bio has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

In the previous week, Adial Pharmaceuticals had 4 more articles in the media than Passage Bio. MarketBeat recorded 7 mentions for Adial Pharmaceuticals and 3 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.62 beat Adial Pharmaceuticals' score of 0.45 indicating that Passage Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adial Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Passage Bio's return on equity of -150.88% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	-150.88%	-59.78%
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

Summary

Adial Pharmaceuticals beats Passage Bio on 7 of the 12 factors compared between the two stocks.

Get Adial Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADIL vs. The Competition

Export

Metric	Adial Pharmaceuticals	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.02M	$454.79M	$6.50B	$12.37B
Dividend Yield	N/A	3.88%	2.67%	5.66%
P/E Ratio	-0.35	3.17	24.01	24.71
Price / Sales	N/A	6,488.68	540.55	165.59
Price / Cash	N/A	13.13	27.48	37.92
Price / Book	0.59	88.02	10.55	6.85
Net Income	-$7.98M	-$96.07M	$3.56B	$337.45M
7 Day Performance	27.38%	0.64%	1.54%	2.70%
1 Month Performance	103.99%	0.38%	2.48%	4.60%
1 Year Performance	-67.84%	58.74%	26.49%	32.81%

Adial Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADIL Adial Pharmaceuticals	3.5994 of 5 stars	$2.82 -5.5%	$17.17 +509.8%	-66.0%	$6.02M	N/A	N/A	20	Analyst Downgrade Gap Up
XCUR Exicure	0.9807 of 5 stars	$2.87 -4.1%	N/A	-68.3%	$18.26M	$500K	N/A	50	Short Interest Decrease
MDCX Medicus Pharma	2.4552 of 5 stars	$0.32 -3.9%	$9.00 +2,686.4%	-87.0%	$18.13M	N/A	N/A	N/A	News Coverage Gap Down
AEON AEON Biopharma	0.8198 of 5 stars	$0.71 -3.4%	N/A	-21.5%	$17.84M	N/A	3.92	5	Gap Up
AKTX Akari Therapeutics	3.1568 of 5 stars	$15.29 -1.0%	$89.00 +482.1%	-71.8%	$17.43M	N/A	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADIL) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. XCUR, MDCX, AEON, AKTX, and PASG

How does Adial Pharmaceuticals compare to Exicure?

Summary

How does Adial Pharmaceuticals compare to Medicus Pharma?

Summary

How does Adial Pharmaceuticals compare to AEON Biopharma?

Summary

How does Adial Pharmaceuticals compare to Akari Therapeutics?

Summary

How does Adial Pharmaceuticals compare to Passage Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. XCUR, MDCX, AEON, AKTX, and PASG

How does Adial Pharmaceuticals compare to Exicure?

Which has more volatility and risk, ADIL or XCUR?

Do analysts prefer ADIL or XCUR?

Does the media prefer ADIL or XCUR?

Which has better earnings and valuation, ADIL or XCUR?

Do institutionals and insiders hold more shares of ADIL or XCUR?

Is ADIL or XCUR more profitable?

Summary

How does Adial Pharmaceuticals compare to Medicus Pharma?

Is MDCX or ADIL more profitable?

Do institutionals and insiders have more ownership in MDCX or ADIL?

Does the media refer more to MDCX or ADIL?

Which has better valuation & earnings, MDCX or ADIL?

Do analysts recommend MDCX or ADIL?

Which has more volatility & risk, MDCX or ADIL?

Summary

How does Adial Pharmaceuticals compare to AEON Biopharma?

Which has more volatility & risk, AEON or ADIL?

Do analysts rate AEON or ADIL?

Do institutionals & insiders hold more shares of AEON or ADIL?

Which has better earnings & valuation, AEON or ADIL?

Does the media prefer AEON or ADIL?

Is AEON or ADIL more profitable?

Summary

How does Adial Pharmaceuticals compare to Akari Therapeutics?

Is ADIL or AKTX more profitable?

Which has more volatility & risk, ADIL or AKTX?

Do analysts recommend ADIL or AKTX?

Which has better valuation and earnings, ADIL or AKTX?

Do institutionals and insiders have more ownership in ADIL or AKTX?

Does the media refer more to ADIL or AKTX?

Summary

How does Adial Pharmaceuticals compare to Passage Bio?

Do insiders & institutionals hold more shares of PASG or ADIL?

Which has stronger earnings & valuation, PASG or ADIL?

Do analysts rate PASG or ADIL?

Which has more volatility & risk, PASG or ADIL?

Does the media prefer PASG or ADIL?

Is PASG or ADIL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools